Short-circuiting pancreatic cancer: A potential RNA therapy

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It’s also the most common form of the disease. Potential treatments typically target a key mutated oncogene called KRAS. In some cases, PDAC tumors with these mutations have resisted therapeutic efforts. However, combination therapies involving alternative drug targets may one day help clinicians overwhelm these defenses.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup